Iridian Asset Management’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-38,906
| Closed | -$1.02M | – | 92 |
|
|
2020
Q3 | $1.02M | Sell |
38,906
-21,900
| -36% | -$610K | 0.02% | 63 |
|
|
2020
Q2 | $1.63M | Sell |
60,806
-27,635
| -31% | -$623K | 0.04% | 55 |
|
|
2020
Q1 | $1.59M | Sell |
88,441
-19,562
| -18% | -$371K | 0.04% | 54 |
|
|
2019
Q4 | $1.92M | Sell |
108,003
-4,354,430
| -98% | -$75.4M | 0.03% | 55 |
|
|
2019
Q3 | $69.2M | Sell |
4,462,433
-388,796
| -8% | -$6.4M | 1.08% | 38 |
|
|
2019
Q2 | $83.3M | Sell |
4,851,229
-2,158,837
| -31% | -$34.8M | 1.2% | 42 |
|
|
2019
Q1 | $113M | Sell |
7,010,066
-2,017,098
| -22% | -$32.7M | 1.44% | 38 |
|
|
2018
Q4 | $132M | Sell |
9,027,164
-201,235
| -2% | -$3.21M | 1.77% | 31 |
|
|
2018
Q3 | $168M | Buy |
9,228,399
+967,923
| +12% | +$17M | 1.68% | 31 |
|
|
2018
Q2 | $139M | Buy |
8,260,476
+68,098
| +0.8% | +$1.29M | 1.29% | 41 |
|
|
2018
Q1 | $160M | Sell |
8,192,378
-582,695
| -7% | -$11.3M | 1.44% | 35 |
|
|
2017
Q4 | $178M | Sell |
8,775,073
-1,230,879
| -12% | -$22.6M | 1.5% | 36 |
|
|
2017
Q3 | $174M | Sell |
10,005,952
-603,041
| -6% | -$8.17M | 1.48% | 35 |
|
|
2017
Q2 | $136M | Buy |
10,608,993
+208,605
| +2% | +$2.79M | 1.2% | 44 |
|
|
2017
Q1 | $135M | Sell |
10,400,388
-339,025
| -3% | -$4.29M | 1.21% | 42 |
|
|
2016
Q4 | $106M | Buy |
10,739,413
+1,449,389
| +16% | +$15.9M | 0.98% | 47 |
|
|
2016
Q3 | $112M | Buy |
9,290,024
+1,098,750
| +13% | +$11.2M | 0.98% | 42 |
|
|
2016
Q2 | $70.7M | Sell |
8,191,274
-554,250
| -6% | -$5.47M | 0.65% | 44 |
|
|
2016
Q1 | $82.8M | Buy |
8,745,524
+61,340
| +0.7% | +$577K | 0.7% | 42 |
|
|
2015
Q4 | $150M | Buy |
8,684,184
+500,181
| +6% | +$7.97M | 1.24% | 34 |
|
|
2015
Q3 | $110M | Sell |
8,184,003
-1,478,660
| -15% | -$29.7M | 0.93% | 38 |
|
|
2015
Q2 | $218M | Buy |
9,662,663
+1,454,340
| +18% | +$25.6M | 1.72% | 28 |
|
|
2015
Q1 | $117M | Buy |
8,208,323
+934,258
| +13% | +$13.5M | 0.99% | 40 |
|
|
2014
Q4 | $70.2M | Buy |
7,274,065
+338,970
| +5% | +$3.01M | 0.65% | 40 |
|
|
2014
Q3 | $63.1M | Buy |
6,935,095
+735,410
| +12% | +$7M | 0.65% | 42 |
|
|
2014
Q2 | $61.3M | Buy |
6,199,685
+2,967,531
| +92% | +$25.2M | 0.63% | 42 |
|
|
2014
Q1 | $41.1M | Buy |
3,232,154
+1,063,999
| +49% | +$15.8M | 0.47% | 41 |
|
|
2013
Q4 | $32.5M | Buy |
2,168,155
+2,098,365
| +3,007% | +$27M | 0.38% | 41 |
|
|
2013
Q3 | $770K | Buy |
+69,790
| New | +$581K | 0.01% | 48 |
|
Other funds holding HALO
BG
SCM
Iridian Asset Management's HALO Position: Q4 2020 in Review
Iridian Asset Management sold out of Halozyme (HALO) in Q4 2020, closing a stake of 38,906 shares — an estimated $1.02M sold.
Iridian Asset Management first reported a position in HALO in Q3 2013 and held it in 29 quarters. The position peaked at $218M in Q2 2015. 342 funds tracked by Wall St. Rank hold HALO as of Q4 2020.
- Iridian Asset Management reported no remaining Halozyme position as of Q4 2020 after selling out during the quarter.
- Iridian Asset Management sold 38,906 Halozyme shares in Q4 2020, an estimated $1.02M.
- Iridian Asset Management first reported a position in Halozyme in Q3 2013 and held it in 29 quarters.
- Iridian Asset Management's Halozyme position peaked at $218M in Q2 2015.
- 342 funds tracked by Wall St. Rank held Halozyme as of Q4 2020.
Based on Iridian Asset Management's 13F filing for Q4 2020, filed 8 Feb 2021.